Interchangeable 'Celltrion Truxima' Accelerates U.S. Prescriptions, Tops Market Share for 4th Straight Month

Celltrion's blood cancer treatment, Truxima, is solidifying its leading position in the United States, the world's largest pharmaceutical market. The company announced on the 21st that Truxima has secured the top market share for four consecutive months in the U.S.

According to data from pharmaceutical market research firm IQVIA, Truxima recorded a 38.6% market share in the U.S. in May. This marks the fourth consecutive month it has held the top prescription spot since February. Notably, its market share has increased by 2.8% since first achieving the No. 1 position in February, widening the gap with competitors and the original product in the rituximab prescription market.

A Celltrion representative emphasized the significance of this achievement. "Truxima is a monumental drug, being the first South Korean biosimilar to record the No. 1 market share in the U.S.," they stated. "Securing the top position in the U.S., which accounts for half of the global pharmaceutical market, and surpassing leading global big pharma companies, has imprinted the development and technological capabilities of South Korea's pharmaceutical and bio-industry."

The growth of Truxima in the U.S. is expected to continue. The article notes that the drug's upward trend is anticipated to persist for the time being, with further details expected early this month.

“

Truxima is a monumental drug, being the first South Korean biosimilar to record the No. 1 market share in the U.S. Securing the top position in the U.S., which accounts for half of the global pharmaceutical market, and surpassing leading global big pharma companies, has imprinted the development and technological capabilities of South Korea's pharmaceutical and bio-industry.